1. Home
  2. AMST vs XBIO Comparison

AMST vs XBIO Comparison

Compare AMST & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amesite Inc.

AMST

Amesite Inc.

HOLD

Current Price

$0.83

Market Cap

8.2M

Sector

Technology

ML Signal

HOLD

Logo Xenetic Biosciences Inc.

XBIO

Xenetic Biosciences Inc.

HOLD

Current Price

$3.15

Market Cap

7.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMST
XBIO
Founded
2017
N/A
Country
United States
United States
Employees
N/A
2
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.2M
7.2M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
AMST
XBIO
Price
$0.83
$3.15
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
745.4K
14.2K
Earning Date
05-13-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
40.46
N/A
EPS
N/A
N/A
Revenue
$110,459.00
N/A
Revenue This Year
N/A
$2.81
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.85
$1.90
52 Week High
$4.78
$13.93

Technical Indicators

Market Signals
Indicator
AMST
XBIO
Relative Strength Index (RSI) 30.07 53.48
Support Level N/A $2.94
Resistance Level $2.07 $3.69
Average True Range (ATR) 0.27 0.15
MACD -0.03 -0.02
Stochastic Oscillator 2.88 52.38

Price Performance

Historical Comparison
AMST
XBIO

About AMST Amesite Inc.

Amesite Inc is an artificial intelligence-driven platform and course designer that rapidly provides customized, high-performance and scalable online products for schools and businesses. The company helps educational institutions and businesses improve learning as their technology partner, delivering a disruptive technology driven by AI and offers a constellation of services that help partners implement new programs, and improve existing ones. Its customers are Enterprises, universities, and K-12 schools.

About XBIO Xenetic Biosciences Inc.

Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.

Share on Social Networks: